Professional Documents
Culture Documents
INTRODUCTION
1.1 BACKGROUND
As recently as 10 years ago, few options for treat- ment and care were available to
those affected by multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant
tuberculosis (XDR-TB).a Later, accumulating evidence indicated that the pro- grammatic
management of M/XDR-TB was not only feasible but also cost effective. The World Health
Organization (WHO) has recognized M/XDR-TB as a major challenge to be addressed as
part of the Stop TB strategy, launched in 2006. In April 2009, WHO convened a ministerial
meeting of countries with a high burden of MDR-TB in Beijing, China, pav- ing the way in
May 2009 for the 62nd World Health Assembly to adopt resolution WHA62.15 on pre-
vention and control of MDR-TB and XDR-TB. The resolution urges Member States to take
action on multiple fronts towards achieving universal access to diagnosis and treatment of
M/XDR-TB by 2015.1,2
CHAPTER II
THEORITICAL REVIEW
2.1 DEFENITION
2.2 ETIOLOGY
Drug resistance surveillance data suggest that more cases of MDR tuberculosis occur
among new cases of tuberculosis than among previously treated cases, although the pro-
portion in the previously treated group is much higher.164 In 2010, 30 countries with anti-
tuberculosis drug resistance surveillance data were each estimated to have more than 700
multidrug-resistant tuberculosis cases among their notified cases each year. Patients who had
not had previous treatment comprised a median of 54% of the MDR cases. The occurrence of
MDR TB in a new patient is an indication that MDR organisms are spreading in a
community. Although case-finding efforts for MDR tuberculosis should first prioritize
previously treated patients for drug sensitivity testing, identification of all MDR TB cases
will require screening for drug resistance in a much wider group of pat patients.1,4,5
More recently, strains of M. tuberculosis with resistance patterns beyond XDR tuberculo- sis
have been described. The available evidence suggests that treatment outcomes are worse
when resistance patterns become more complicated.1,3,4
Assessing risk for drug resistance
This section describes the methods for designing a treatment regimen. It applies to
standardized, empirical and individualized regimens.
General principles The following are the basic principles involved in any regimen design:
CONCLUSION
3.1 CONCLUSION